Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.165 USD | +7.07% | +6.91% | -0.95% |
Mar. 06 | Vanda Pharmaceuticals : FDA Rejects Hetlioz Expanded Label | DJ |
Mar. 06 | Vanda Pharmaceuticals Announces FDA Update for Supplemental NDA for HETLIOZ in the Treatment of Insomnia | CI |
Evolution of the average Target Price on Vanda Pharmaceuticals Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Vanda Pharmaceuticals Inc.
Jefferies & Co. | |
BofA Securities | |
Citigroup |
EPS Revisions
- Stock
- Equities
- Stock Vanda Pharmaceuticals Inc. - Nasdaq
- Consensus Vanda Pharmaceuticals Inc.